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(P	=	.02	 for	 both).	A	weak	 correlation	between	MRCP	 score	 for	 extra-	hepatic	 bile	
ducts	 and	 liver	 transplantation/death	 was	 found	 (Spearman’s	 ρ	=	.362,	 95%	 CI:	
0.080-	0.590,	P	=	.022).	A	weak	correlation	between	intra-	(Spearman′s	ρ	=	.322,	95%	
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1  | INTRODUC TION
Primary	 sclerosing	 cholangits	 (PSC)	 is	 a	 chronic	 inflammatory	 and	
fibrotic	disease,	involving	the	intra-	and	extrahepatic	biliary	tree.1,2 






been	 considered	 the	 gold	 standard	 for	 diagnosis	 of	 PSC,	 since	
it	 provides	 a	 direct	 visualization	of	 the	 entire	 biliary	 tree.7	 The	






frequent	 one.10	 A	 meta-	analysis	 has	 shown	 that	 imaging	 with	
magnetic	 resonance	 cholangiopancreatography	 (MRI-	MRCP)	 is	
an	accurate,	non-	invasive	and	cost-	effective	alternative	method	
for	diagnosis	 and	 follow-	up	of	PSC.11	 For	 these	 characteristics,	
MRI-	MRCP	 may	 play	 an	 important	 role,	 especially	 in	 patients	
who	 need	 a	 long	 follow-	up,	 like	 children	 and	 young	 adults.12 





death	make	 PSC	 “an	 orphan	 disease”,	 which	 results	 in	 difficulties	
to	plan	 randomized	 clinical	 trial	 on	new	 treatments.	Due	 to	 these	
























2  | MATERIAL S AND METHODS
2.1 | Study design
This	 is	 a	 single-	centre	observational	 longitudinal	 retrospective	co-
hort	study.













All	 data	 (ie	 clinical,	 biochemical,	 histology,	 cholangiography	
and	therapy)	are	prospectively	collected	in	the	PSC	registry;	over	












tion	 of	 the	 severity	 of	 biliary	 changes	 in	 PSC	 is	 only	
moderate.
•	 The	severity	of	biliary	changes	in	MRCP	and	ERCP	is	as-





images	 shows	 only	weak	 correlation	with	 strong	 end-
points	(ie	liver	transplantation	and	death)	in	PSC.





2.3 | ERCP procedures and images
All	 the	 procedures	were	 performed	 by	 the	 same	 experienced	 en-
doscopists	 (M.F.,	K.J.,	A.T.)	with	the	patient	 in	prone	position	with	
the	 assistance	 of	 an	 anesthesiologist.	 Cannulation	was	 performed	
using	 a	 papillotomy	 knife	 (Jagtome	 RX;	 Boston	 Scientific,	 Miami,	
Florida,	USA®)	and	a	0.035-	in,	450	cm	guide	wire	(Jagwire;	Boston	
Scientific®).	After	a	successful	cannulation,	biliary	papillotomy	was	






















logically	 corresponding	 to	 low-	grade	 dysplasia,	 4	=	high	 suspicion	




(Avanto,	 Avanto	 Fit,	 Aera	 or	 Symphony	 Tim	 Siemens	 Healthcare,	
Erlangen,	Germany®;	 Signa	HDxt	or	Optima	MR450w	GE	Medical	
Systems,	 Milwaukee,	 Wis®)	 or	 3.0	 T	 scanners	 (Verio,	 Siemens	
Healthcare,	 Erlangen,	 Germany®).	 Fasting	 for	 at	 least	 3	hours	 be-
fore	 examination	was	 required.	Pineapple	 juice	 (200	mL	5-	10	min-
utes	before	the	examinations)	was	used	as	a	negative	oral	contrast	
agent	 to	 diminish	 the	 signal	 of	 the	 bowel	 lumen	 and	 to	 improve	
visualization	of	 the	pancreatic-	biliary	 systems.	 The	 imaging	proto-
col	included	coronal	and	axial	T2-	weighted	sequences,	an	axial	T2-	
weighted	sequence	with	fat-	suppression,	axial	 in	and	out	of	phase	
T1-	weighted	 gradient	 echo	 sequence	 and	 diffusion-	weighted	 se-
quences	with	three	b-	values	(50,	400	and	800)	and	ADC	map.	MRCP	
images	 included	 a	 respiratory	 triggered	 3D	 heavily	 T2-	weighted	
F IGURE  1 Diagnosis	and	follow-	up	in	patients	with	primary	sclerosing	cholangitis	at	Helsinki	University	Hospital
PATIENT WITH SUSPICION OF PSC
• Clinical (Symptoms/Signs, + IBD)
• Biochemical (elevated S-ALP)
• AMA negave
• + Liver biopsy   
MRI-MRCP
ERCP:
• Modified Amsterdam PSC score
• Brush cytology + DNA-Flow cytometry
• Modified Amsterdam PSC score < 3
• Brush cytology benign
Ultra-sound + ERCP every 3 years
• Modified Amsterdam PSC score < 3
• Brush cytology benign















• Repeatedly confirmed dysplasia/aneuploidy
• No suspicion of cancer at imaging Evaluaon for liver transplantaon
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sequence	 in	 the	coronal	plane	and	a	breath-	hold	 thick	slab	single-	
shot	heavily	T2-	weighted	sequence	 in	coronal	and	oblique	coronal	
projections.	Contrast-	enhanced	images	were	acquired	with	an	axial,	




ject.	All	 the	MRI-	MRCP	cholangiography	 images	were	 reviewed	 in	
consensus	by	two	experienced	abdominal	radiologists	(K.L.	and	E.L.),	
blinded	to	clinical	data	and	ERCP	results.	For	the	study	purpose,	the	
images	were	 re-	scored	 using	 the	modified	Amsterdam	PSC	 score,	





All	 the	 demographic	 (ie	 gender,	 age)	 and	 clinical	 (ie	 associated	 in-
flammatory	 bowel	 disease	 [IBD],	 overlapping	 with	 autoimmune	












0	=	no	 changes,	 1-	2	=	mild	 changes	 and	 3-	4	=	severe	 changes).	
Peribiliary	 enhancement	was	 classified	 as	 no	 enhancement,	 en-
hancement	<2	mm	and	enhancement	≥2	mm	because	there	were	
few	cases	with	≥6	mm	group	 (n	=	3).	Agreement	between	ERCP	
and	 MRCP	 modified	 Amsterdam	 PSC	 score	 was	 tested	 with	
weighted	kappa-	statistic	with	quadrate	weights.	The	McNemar-	
Bowker	 test	 was	 used	 to	 evaluate	 differences	 in	 pair	 ordinal	
variables.	 Differences	 between	 variables	 were	 tested	 with	 the	
Fisher′s	 exact	 test	 when	 categorical,	 with	 the	 linear-	by-	linear	
association	 test	when	ordinal	 and	with	 the	Mann-	Whitney	Test	
when	 continuous.	 The	 Spearman′s	 ρ	 was	 calculated	 for	 ordinal	
variables	 with	 bootstrapped	 (500	 replications)	 95%	 confidence	
intervals	(CI).
2.8 | Ethical consideration
In	 Finland	patient	 consent	 to	MRI-	MRCP	 and	ERCP	procedures	 is	
obtained	orally.	The	Local	Ethics	Committee	of	Helsinki	University	





Forty-	eight	 patients	 with	 MRI-	MRCP	 within	 ±3	months	 from	
ERCP,	 were	 identified	 from	 the	 PSC	 registry	 (male:	 31,	 median	











score	 on	 MRI-	MRCP	 cholangiography	 changes	 were	 the	 same	 or	
TABLE  1 Modified	Amsterdam	PSC	score
Amsterdam score Modified score Description
Intrahepatic	bile	ducts
 0 0 No	visible	abnormalities
 I 1 Ductular	irregularities
 I 2 Multiple	calibre	
changes;	minimal	
dilatation
 II 3 Multiple	strictures;	
saccular	dilatations,	
decreased	arborisation





 0 0 No	visible	abnormalities
 I 1 Slight	irregularities	of	
duct	contour,	no	
stricture
 II 2 Segmental	stricture
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even	higher	 than	that	one	detected	on	ERCP	cholangiography.	No	
patient	had	post	ERCP-	cholangitis.











3.3 | ERCP- MRCP modified Amsterdam PSC 




CA	 19-	9	 levels	 (P = .018 and P	=	.030,	 respectively),	 but	 observed	
no	statistically	significant	association	with	other	markers	of	disease	
activity	 (ie	 ALT,	 biliary-	neutrophils,	 IEL,	 cytological	 classification).	











found	 (Spearman′s	 ρ	=	.362,	 95%	 CI:	 0.080-	0.590,	 P	=	.022),	 but	
not	for	intrahepatic	bile	ducts	(Spearman′s	ρ	=	.175,	95%	CI:	0.122-	
0.442,	P	=	.315).
3.4 | MRI peribiliary enhancement and markers of 




Intrahepatic	 peribiliary	 enhancement	 was	 detected	 in	 40/52	
MRIs	 (77%),	 being	 <2	mm	 in	 14	 cases	 and	 ≥2	mm	 in	 26	 cases.	
Extrahepatic	peribiliary	enhancement	was	detected	in	44/52	MRIs	
(85%),	being	<2	mm	in	13	cases	and	≥2	mm	in	31	cases.
A	 weak	 correlation	 between	 MRI	 intra-	 (Spearman′s	 ρ	=	.322,	
95%	 CI:	 0.048-	0.551,	 P	=	.022)	 and	 extrahepatic	 (Spearman′s	
ρ	=	.319,	 95%	 CI:	 0.045-	0.549,	 P	=	.025)	 peribiliary	 enhancement	



































0 (n = 0) 1- 2 (n = 23) 3- 4 (n = 32)
MRCP	score
 0 0/0	(0%) 1/23	(4%) 0/32	(0%)
	1-	2 0/0	(0%) 13/23	(56%) 6/32	(19%)
	3-	4 0/0	(0%) 9/23	(39%) 26/32	(81%)
Extra- hepatic
ERCP score
0 (n = 11) 1- 2 (n = 33) 3- 4 (n = 11)
MRCP	score
 0 3/11	(27%) 1/33	(3%) 0/11	(0%)
	1-	2 7/11	(64%) 25/33	(76%) 2/11	(18%)








end-	stage	 liver	 disease	 and	 six	 patients	 for	 suspicion	 of	 neoplasia).	
One	patient	(2%)	died	from	cholangiocarcinoma.	Characteristics	of	the	
seven	patients	with	suspicion	of	malignancy	or	cholangiocarcinoma	































ERCP modified Amsterdam PSC score
Intrahepatic Extra- hepatic














































 0 n = 8 3	(37%) 5	(62%) 1.00 3	(37%) 4	(50%) 1	(12%) .41
 1 n = 33 14	(42%) 19	(58%) 6	(18%) 19	(58%) 8	(24%)
 2 n = 14 6	(43%) 8	(57%) 2	(14%) 9	(64%) 3	(21%)
Cytologic	classification	n	=	55a
 1 n = 8 4	(50%) 4	(50%) .83 3	(37%) 4	(50%) 1	(12%) .06
 2 n = 40 16	(40%) 24	(60%) 7	(17%) 26	(65%) 7	(17%)
 3 n = 5 1	(20%) 4	(80%) 1	(20%) 1	(20%) 3	(60%)















of	 the	most	 promising	 surrogate	markers	 for	 clinical	 trials	 in	PSC.	
Enhanced	liver	fibrosis	(ELF)	test,	a	panel	incorporating	three	direct	
serum	markers	of	fibrosis	in	an	algorithm	(hyaluronic	acid,	tissue	in-












ficity29	 for	 the	 diagnosis	 of	 cholangiocarcinoma	 in	 PSC	 patients,	
which	hampers	the	value	of	this	parameter.23	Finally,	Färkkilä	et	al	










for	 its	 higher	 accuracy	 in	 detecting	 early	 changes.13	 Indeed,	 diag-
nosis	of	small-	duct	PSC	can	be	extremely	challenging	without	high-	
quality	 ERCP.	 Secondly,	 ERCP	 allows	 to	 assess	 the	 individual	 risk	
of	 disease	 progression	 based	 on	 brush	 cytology.9	 A	meta-	analysis	
including	six	studies	published	between	2000	and	2006	concluded	
that	 MRCP	 has	 a	 very	 high	 specificity	 (Sp	 0.94;	 0.86-	0.98)	 and	
TABLE  5 Association	between	MRCP	modified	Amsterdam	PSC	score	and	markers	of	PSC	activity	and	severity	(n	=	55)
MRCP modified Amsterdam PSC score
Intrahepatic Extra- hepatic














































 0 n = 7 3	(43%) 4	(57%) 1.00 2	(28%) 4	(57%) 2	(28%) .71
 1 n = 31 10	(32%) 21	(68%) 0	(0%) 18	(58%) 13	(42%)
 2 n = 14 5	(36%) 9	(64%) 2	(14%) 10	(71%) 2	(14%)
Cytologic	classification	n	=	52a
 1 n = 7 4	(57%) 3	(43%) 1.00 2	(28%) 5	(71%) 1	(14%) .08
 2 n = 39 12	(31%) 27	(69%) 2	(5%) 24	(61%) 13	(33%)
 3 n = 4 0	(0%) 4	(100%) 0	(0%) 2	(50%) 2	(50%)

















ous	 in	many	of	 the	 included	 studies	 (in	 some	 study	 percutaneous	





























































































	0	n	=	6 3	(50%) 2	(33%) 1	(17%) .13 2	(33%) 1	(17%) 3	(50%) .09
 1 n = 30 7	(23%) 6	(20%) 17	(57%) 6	(20%) 8	(27%) 16	(53%)
 2 n = 14 2	(14%) 4	(29%) 8	(57%) 0	(0%) 4	(29%) 10	(71%)
IEL	n	=	50a
 0 n = 17 5	(29%) 4	(23%) 8	(47%) .59 2	(12%) 6	(35%) 9	(53%) 1.00
 1 n = 33 7	(21%) 8	(24%) 18	(54%) 6	(18%) 7	(21%) 20	(61%)
Cytologic	classification	n	=	50a
 1 n = 4 2	(50%) 2	(50%) 0	(0%) .02* 2	(50%) 1	(25%) 1	(25%) .03*
 2 n = 39 10	(26%) 8	(20%) 21	(54%) 6	(15%) 11	(28%) 22	(56%)
 3 n = 5 0	(0%) 2	(40%) 3	(60%) 0	(0%) 1	(20%) 4	(80%)
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needs	to	be	confirmed	in	further	prospective	studies.	Severity	of	dis-
ease	evaluated	by	MRCP	was	not	associated	with	biliary	neoplasia.


















ogy,	which	 is	usually	 located	 into	epithelium	 (ie	biliary-neutrophils	
and	IEL).	Finally,	persistent	inflammation	induces	damage	of	cholan-
giocytes	and	progressive	fibrosis34	and	trough	a	multistep	transition	
(ie	 normal	 epithelium,	 metaplasia,	 dysplasia)	 to	 cholangiocarci-
noma.35	However,	whether	defined	periductal	biliary	 inflammation	
in	the	MRI	(ie	presence	and	thickness)	can	be	used	to	discriminate	
among	 inflammatory,	 preneoplastic	 and	 neoplastic	 lesions	 needs	
to	 be	 confirmed	 in	 the	 future	 in	 other	 large	 prospective	 studies.	
In	 this	 study	peribiliary	enhancement	 thickness	was	classified	 into	 
<2,	2-	6,	>6	mm,	although	 the	 last	 two	groups	were	 finally	merged	
together	(≥2	mm)	because	there	were	only	3	cases	in	>6	mm	group.	
Still,	the	diagnostic	characteristics	of	brush	cytology	are	largely	de-





















This	was	 the	 first	 study	 evaluating	 the	 role	 of	 ERCP	 and	MRI-	







PSC patients with suspicion or malignancy
1 2 3 4 5 6 7
Cytologic	classification	at	
ERCP	index
3 3 3 3 3a 4 4a
Enhancement	on	MRI	
(intra-	and	extrabile	ducts)
<2 mm ≥2	mm ≥2	mm ≥	2	mm ≥2	mm ≥2	mm ≥2	mm
Number	of	ERC	+	brush	
cytology	to	confirm
2 2 1 1 2 1 3
Liver	transplantation + − + + + + +
Finding	in	explanted	liver CC − HGD CC 
Cirrhosis
CC LGD HGD
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